Efficacy of escitalopram in patients with severe depression: a pooled analysis: Escitalopram in Severe Depression
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Escitalopram is an effective, well-tolerated treatment for major depressive disorder in both primary and specialist settings. This analysis compared the efficacy of escitalopram with citalopram in the treatment of patients with severe depression [defined as a score of > or =30 Montgomery-Asberg Depression Rating Scale (MADRS)]. Data from three clinical trials were used for this pooled analysis. A total of 506 severely depressed patients were included (169 received escitalopram, 171 citalopram and 166 placebo). Mean change from baseline in MADRS total scores (primary efficacy parameter) was significantly higher in the escitalopram-treated group compared with the citalopram-treated group (p = 0.003). There was a significant difference in response between escitalopram and citalopram (56 vs. 41%, respectively, p = 0.007). Results from secondary efficacy parameters (Hamilton rating for depression and Clinical Global Impression of Improvement and Severity scales) were consistent with previous results. The benefits in severe depression of escitalopram vs. citalopram were so demonstrated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing antidepressant activity in rodents: recent developments and future needs
Cryan, J. F., Markou, A., & Lucki, I. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02017-5 · Cited by 1,551 · cited 1×
“Escitalopram is the pharmacologically active enantiomer of citalopram (22) as shown by the results of a number of behavioural tests of antidepressant and anxiolytic activity performed in vitro and in vivo in rats ( 23 ).”
Background
Cited by
The burden of severe depression: A review of diagnostic challenges and treatment alternatives
Nemeroff, C. B. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.05.008 · Cited by 295
Placebo-controlled trial of agomelatine in the treatment of major depressive disorder
Kennedy, S. H., & Emsley, R. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.09.002 · Cited by 294
Montgomery, S. A., & Möller, H.-J. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32832a8eb2 · Cited by 121
Klein, N., Sacher, J., Geiss-Granadia, T., Attarbaschi, T., Mossaheb, N., Lanzenberger, R., Pötzi, C., Holik, A., Spindelegger, C., Asenbaum, S., et al. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0486-0 · Cited by 77
Escitalopram: A Review of its Use in the Management of Major Depressive Disorder in Adults
Garnock-Jones, K. P., & McCormack, P. L. (2010) · CNS Drugs · doi:10.2165/11204760-000000000-00000 · Cited by 66
Metadata
- Authors
- Llorca, P.-M., Azorin, J.-M., Despiegel, N., & Verpillat, P.
- Venue
- International Journal of Clinical Practice
- Publisher
- Hindawi Limited
- Published
- 2005-02-23
- Volume
- 59
- Issue
- 3
- Pages
- 268-275
- ISSN
- 1368-5031 (ISSN-L)
- OpenAlex
- W1655045766
- Cited by
- 74
- References
- 1
- FWCI
- 6.50
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of escitalopram in patients with severe depression: a pooled analysis: Escitalopram in Severe Depression. https://app.cochat.ai/papers/10.1111/j.1742-1241.2005.00440.x
- The paper
- Llorca, P.-M., Azorin, J.-M., Despiegel, N., & Verpillat, P. (2005). Efficacy of escitalopram in patients with severe depression: a pooled analysis: Escitalopram in Severe Depression. International Journal of Clinical Practice. https://doi.org/10.1111/j.1742-1241.2005.00440.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.